ChronoScale Corporation Common Stock (NASDAQ:CHRN) Earns Outperform Rating from Analysts at Northland Securities

Investment analysts at Northland Securities began coverage on shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN) in a research note issued on Friday, Briefing.com reports. The firm set an “outperform” rating and a $32.00 price target on the stock. Northland Securities’ price objective points to a potential upside of 58.97% from the company’s previous close.

Separately, Weiss Ratings raised ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, August 24th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $19.00.

ChronoScale Corporation Common Stock Trading Up 7.9%

Shares of ChronoScale Corporation Common Stock stock opened at $20.13 on Friday. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of -3.74 and a beta of 0.98. ChronoScale Corporation Common Stock has a fifty-two week low of $3.50 and a fifty-two week high of $30.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.51 and a current ratio of 0.51. The stock has a 50 day moving average of $21.49 and a 200 day moving average of $17.04.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last posted its earnings results on Wednesday, August 19th. The company reported ($0.12) EPS for the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. The business had revenue of $18.40 million during the quarter. As a group, research analysts predict that ChronoScale Corporation Common Stock will post -0.1 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc boosted its holdings in shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN) by 104.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,338 shares of the company’s stock after buying an additional 1,195 shares during the quarter. Roble Belko & Company Inc owned 0.07% of ChronoScale Corporation Common Stock worth $25,000 as of its most recent SEC filing. Institutional investors own 6.42% of the company’s stock.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.